Drug Profile
Research programme: cancer therapeutics - CiMaas
Alternative Names: CIM 301; Natural killer cell engaging antibody - CiMaas; Natural killer cell therapy - CiMaasLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator CiMaas
- Developer Cancer Research Technology; CiMaas; University of Copenhagen
- Class Antibodies; Bispecific antibodies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Cancer in Netherlands (Parenteral)
- 06 Oct 2023 CiMaas files for patent protection for a new method for the feeder cell preparation in support of its NK cell therapy
- 28 Apr 2021 Preclinical development in Cancer is ongoing in Netherlands (CiMaas pipeline, April 2021)